|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-13
|
$360,039
|
$176,419
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-26S1
|
$487,529
|
$53,628
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VCU Minority-Based Community Clinical Oncology Program
|
2U10CA052784-20
|
$359,518
|
$53,928
|
ROBERTS, JOHN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-20S1
|
$100,001
|
$15,000
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-20S2
|
$197,549
|
$29,632
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-35S1
|
$99,949
|
$999
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-35S2
|
$73,975
|
$740
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-35S3
|
$98,980
|
$990
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
5P30CA014089-35
|
$6,464,088
|
$64,641
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-26
|
$1,751,531
|
$192,668
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-24S6
|
$1,444,105
|
$72,205
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-24S7
|
$98,815
|
$4,941
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
University of Texas SPORE in Lung Cancer
|
5P50CA070907-13
|
$2,300,000
|
$115,000
|
MINNA, JOHN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
University of Rochester Cancer Center CCOP Research Base
|
3U10CA037420-25S1
|
$192,830
|
$44,351
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-26
|
$2,671,183
|
$614,372
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-23S1
|
$100,000
|
$1,000
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
5P30CA046592-23
|
$5,994,681
|
$59,947
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Colorado Southwest Oncology Group
|
2U10CA042777-23
|
$231,603
|
$76,429
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-15S1
|
$99,999
|
$2,000
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
University of California, Irvine Cancer Center Support Grant
|
5P30CA062203-15
|
$1,304,625
|
$26,093
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Understanding the biology of taxane response in the context of ETS rearranged pro
|
1R21CA143496-01A1
|
$257,303
|
$257,303
|
Rickman, David
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
Understanding resistance to HER family tyrosine kinase inhibitors
|
5R01CA122216-04
|
$253,936
|
$63,484
|
MOASSER, MARK
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
U10 Full Member Application Affiliated with SWOG
|
2U10CA105409-07
|
$325,685
|
$107,476
|
HERBST, ROY
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor -Targeting Chemotherapeutic Agents
|
5R01CA103314-19
|
$323,606
|
$323,606
|
OJIMA, IWAO
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Tubulin Mutations and Paclitaxel Resistance
|
5R01CA085935-10
|
$263,242
|
$263,242
|
CABRAL, FERNANDO
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
Treatment Effects on Tumor 18F-Choline Metabolism in Advanced Prostate Cancer
|
5R21CA139687-02
|
$383,240
|
$383,240
|
Kwee, Sandi
|
QUEEN'S MEDICAL CENTER
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-07
|
$287,384
|
$287,384
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Transgenic Models for Prostate and Breast Cancer
|
ZIA BC 005740
|
$796,314
|
$15,926
|
Green, Jeffrey
|
CCR (NCI)
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-14
|
$246,768
|
$123,384
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
2U10CA035415-27
|
$787,658
|
$78,766
|
MOWAT, REX
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
1U10CA142559-01
|
$188,304
|
$62,140
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
2R01CA115483-06
|
$302,871
|
$151,436
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-06S1
|
$8,892
|
$4,446
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-06S2
|
$47,903
|
$23,952
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-06S3
|
$10,070
|
$5,035
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
2P50CA083639-11
|
$2,231,452
|
$133,887
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Role of t-Darpp in Esophageal Adenocarcinoma
|
5R01CA133738-02
|
$232,625
|
$116,313
|
EL-RIFAI, WAEL
|
VANDERBILT UNIVERSITY
|
|
The role of SGK1 in triple-negative breast cancer resistance to treatment
|
1R21CA149472-01
|
$185,250
|
$185,250
|
CONZEN, SUZANNE
|
UNIVERSITY OF CHICAGO
|
|
The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
|
5K23CA121994-05
|
$136,080
|
$34,020
|
Gonzalez-Angulo, Ana
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Gulf Coast MBCCOP
|
5U10CA128536-04
|
$499,869
|
$49,987
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
ZIA SC 010098
|
$405,009
|
$20,250
|
Dahut, William
|
CCR (NCI)
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
2U10CA114671-04
|
$534,190
|
$69,445
|
SOLOMON, WILLIAM
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-04S1
|
$99,947
|
$12,993
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-04S2
|
$147,852
|
$19,221
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Bcl-2-p85/PI3K signaling axis
|
1R01CA140980-01A1
|
$396,325
|
$198,163
|
ZHANG, XIAO-KUN
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
5R01CA077091-07
|
$352,225
|
$352,225
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
Taxol: Mechanisms of Action and Resistance
|
2R01CA077263-10A2
|
$415,000
|
$415,000
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Taxane Resistance in Breast and Ovarian Cancer Cells
|
5R01CA114037-04
|
$297,730
|
$297,730
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
|
5R01CA123159-04
|
$278,768
|
$139,384
|
COLE, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells
|
5R01CA138197-03
|
$473,769
|
$47,377
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
Total relevant funding to Taxol for this search: $74,362,100
|